CTOR Stock Analysis: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.68
-0.02 (-3.39%)
▼
5d:
+3.09%
30d:
-13.05%
90d:
+4.98%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CTOR shows positive signals but monitor for confirmation. Market pricing in 28.0% growth. Moderate conviction.
💡 BUY OPPORTUNITY: CTOR shows positive signals but monitor for confirmation. Market pricing in 28.0% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.68, which is considered slightly low relative to its 30-day fair value range of $0.66 to $0.80. From a valuation perspective, the stock is trading at a premium (Forward PE: 6.8) compared to its historical average (3.2). At these levels, the market is pricing in 28.0% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CTOR is in a downtrend. The price is currently testing key support at $0.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+487.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTOR is in a downtrend. The price is currently testing key support at $0.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+487.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.66 -
$0.80
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 487.9% below Wall St target ($4.00)
- BEARISH: Market expects 28.0% growth - appears too optimistic based on history
Trading Range Analysis
30-Day Trading Range
$0.66 -
$0.80
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.66
Resistance Level
$0.85
Current Trend
Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.80
Wall Street Target
$4.00
(+487.9%)
Valuation Premium vs History
+28.0% premium
PE vs Historical
6.8 vs 3.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+28.0%
(market-implied from PE analysis)
1-Year Target
$0.87
(+28%)
2-Year Target
$1.11
(+64%)
3-Year Target
$1.43
(+110%)
3-Yr Target (if PE normalizes)
(PE: 7→3)
PE COMPRESSION
$0.67
(-1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 03, 2026 6:00 PM ET
Data refreshes hourly during market hours. Next update: 7:00 PM
Data refreshes hourly during market hours. Next update: 7:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |